Tag: schizophrenia

Letter to the Editor: Metabolic Changes in Patients with Schizophrenia Switched from Olanzapine to Asenaprine or Clozapine
By Masaru Nakamura, MD, PhD, and Takahiko Nagamine, MD, PhD Funding/financial disclosures: The author has no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2018;15(7–8):11–14 Dear Editor: The second-generation antipsychotics (SGAs) that focus on dopamine-2 plus serotonin-2A receptor antagonism are first-line treatments […]

Comorbid Insomnia and Psychiatric Disorders: An Update
by Khurshid A. Khurshid, MD, FAASM Dr. Khurshid is Clinical Associate Profressor and Chief of the Neuromodulation and Sleep Disorders Program in the Department of Psychiatry at the University of Florida College of Medicine in Gainsville, Florida. Innov Clin Neurosci. 2018;15(3–4):28–32 Funding: No funding was received for the preparation of this article. Disclosures: The author […]

Letter to the editor: Acute schizophrenia-like psychotic disorder: a critical appraisal of its diagnostic validity through a case series
Dear Editor: In the 10th edition of the International Classification of Diseases (ICD-10) the category “acute and transient psychotic disorder” (ATPD; F23) was introduced, grouping several psychotic conditions that were originally described as separate syndromes.[1] This disorder is characterized by an acute onset of psychotic symptomatology (less than 2 weeks in duration), which is often […]

The 30th Anniversary of PANSS Special Edition
Dear Colleagues: Thirty years ago, the Positive and Negative Syndrome Scale (PANSS) was developed and published by Stanley Kay, Abraham Fiszbein, and Lewis Opler to identify the presence and severity of psychopathology symptoms in patients with psychotic disorders, with the objective of measuring patient characteristics and evaluating change over time using 30 symptoms rated on […]

Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience
by Philip D. Harvey, PhD; Anzalee Khan, PhD; and Richard S. E. Keefe, PhD Dr. Harvey is Professor of Psychiatry and Behavioral Sciences at University of Miami School of Medicine in Miami, Florida. Dr. Khan is Senior Biostatistician at NeuroCog Trials and holds an appointment in the Psychopharmacology Research Program at the Nathan S. Kline […]

Insight and Treatment Outcomes in Schizophrenia: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR
by Philip D. Harvey, PhD; Cynthia O. Siu, PhD; and Antony D. Loebel, MD Dr. Harvey is with the University of Miami Miller School of Medicine in Miami, Florida, and the Research Service of the Bruce W. Carter VA Medical Center in Miami, Florida. Dr. Siu is with COS and Associates Ltd. in Central District, […]

Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency
by Anzalee Khan, PhD; Lora Liharska, MS; Philip D. Harvey, PhD; Alexandra Atkins, PhD; Daniel Ulshen, BA; and Richard S.E. Keefe, PhD Dr. Khan is Senior Biostatistician at NeuroCog Trials and holds an appointment in the Psychopharmacology Research Program at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York. Ms. Liharska is […]

Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model
by Ariana E. Anderson, PhD; Steven P. Reise, PhD; Stephen R. Marder, MD; Maxwell Mansolf, MS; Carol Han, BS; and Robert M. Bilder, PhD Dr. Anderson is with the Department of Psychiatry and Biobehavioral Sciences and the Department of Statistics, Dr. Reise is with the Department of Psychology, Dr. Marder is with the Department of […]

Understanding Antipsychotic Drug Treatment Effects: A Novel Method to Reduce Pseudospecificity of the Positive and Negative Syndrome Scale (PANSS) Factors
by Seth C. Hopkins, PhD; Ajay Ogirala, PhD, Antony Loebel, MD; and Kenneth S. Koblan, PhD Drs. Hopkins, Ogirala, Loebel, and Koblan are with Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts. Funding: Funding was provided by Sunovion Pharmaceuticals Inc. Disclosures: The authors are employees of Sunovion Pharmaceuticals Inc. Abtract: The Positive and Negative Syndrome Scale (PANSS) is the […]